Lusiadas Scientific Journal

Wellens Pattern: A Crucial Marker of Left Coronary Stenosis

2024-07-26T02:38:54-07:00

Esophageal Food Impaction: An Atypical Case

2024-11-23T07:02:50-08:00

Acute Diarrhea in a Patient with HIV Infection: Cystoisospora belli

2024-11-11T08:09:00-08:00

Staphylococcal Scalded Skin Syndrome in a Healthy Adult

2024-12-21T08:49:56-08:00

COVID-19 Vaccine in Children: Current Evidence and Recommendations

2024-12-27T03:19:34-08:00

Vaccination against COVID-19 (coronavirus disease 2019) was a fundamental tool in the pandemic control strategy and its benefits were greater in the groups at higher mortality risk.

Children and adolescents with COVID-19 generally present with mild and often asymptomatic disease, but they may have severe respiratory and/or inflammatory clinical manifestations resulting in hospital admission with around one-third requiring intensive care.

Mortality from COVID-19 in children and young adults is low and the existence of chronic diseases or underlying medical conditions is relevant to clinical severity and prognosis.

Currently, after the end of the pandemic was declared in May 2023, vaccination of children in Portugal no longer covers healthy children, but includes children with immunosuppression and chronic diseases. Following WHO recommendations, several European countries have adopted a similar strategy. Other countries, such as the United States of America (US), continue to vaccinate healthy children as part of the public health strategy to control the disease and improve immunity.

In Portugal, the vaccination of children belonging to risk groups requires the involvement of pediatricians, who are involved in the care of children with diverse chronic diseases in various areas and who may play a relevant role in overcoming vaccine hesitancy of the parents that results from lack of knowledge, misinformation or a mistaken perception of low risk.

Osteogenesis Imperfecta Type III: Case Report and Comprehensive Analysis of Phenotypic Classification, Genetic Causes, and Therapeutic Approaches

2024-08-16T07:53:18-07:00

Osteogenesis imperfecta (OI), known as brittle bone disease, is a genetic condition that affects the extracellular matrix of the skeletal system, causing bone fragility and potential impacts on other organs. Its prevalence varies from approximately 1 in 10 000 to 20 000 births and is associated with various genetic mutations. We report a case of a 14-month-old female patient diagnosed with OI type III, characterized by short stature, dental abnormalities, and bone fragility. Medical history includes effectively treating fevers, gastrointestinal, and respiratory issues. X-rays revealed fractures in bilateral femurs and humeri. She underwent femur surgery and continues to experience frequent fractures, unable to ambulate, under intensive medical care. OI is a genetic condition presenting with severe bone fragility, short stature, and progressive deformities, necessitating accurate diagnosis and effective treatment to improve quality of life.

The 2025 Editorial

2025-03-20T05:39:21-07:00